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Abstract: Alzheimer’s disease is a devastating chronic disease that significantly increases
healthcare costs and affects the quality of life (QoL) of the afflicted patients and their caregivers.
Population aging and other demographic changes may further increase the already staggering
costs of this devastating disease. While few pharmacoeconomic studies have used a prospective
health economics design to assess resource utilization, most studies showed beneficial treatment
effects and suggested potential savings in healthcare costs and reductions in caregiver burden.
Various degrees of cost savings have been reported depending on the type of economic model,
treatment evaluated, and region used in the studies. Direct comparisons of the results are
difficult because different methods have been used in these evaluations. The preference of
patients and families for home care for as long as possible suggests that promoting
noninstitutional care for these patients should become a priority. Continued home care for
patients under pharmacological treatment may reduce caregiver burden, healthcare costs, and
ultimately improve patients’ and caregivers’ QoL.
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Introduction
Alzheimer’s disease (AD), the most common cause of dementia, is a progressive,
neurodegenerative brain disease of unknown etiology that primarily affects the elderly.
The onset of AD is usually insidious. The disease is characterized by loss of memory
and other intellectual abilities with concomitant loss of functional abilities. As the
disease progresses, its victims deteriorate until eventually they are no longer able to
perform the most basic activities of daily living (ADL). Two-thirds to three-fourths
of AD patients are cared for in the community by family members and friends, many
of whom live with the caregiver (Dunkin and Anderson-Hanley 1998). Throughout
the disease, patients often develop behavioral and psychiatric problems that are difficult
to treat and create much stress for the caregivers (Teri et al 1997). The progressive
decline in patients’ cognition, function, behavioral and psychiatric symptoms, and
the tremendous stress faced by the caregivers are often predictive of institutional
placement. Alzheimer’s disease progression from diagnosis to death is usually about
seven to ten years, with pneumonia or sepsis as the usual cause of death (Brookmeyer
et al 2002; Cummings and Cole 2002). Approximately 100000 patients die with AD
each year, making it the fourth leading cause of death in the US (Evans 1990). We
review the impact of AD on the cost of care as well as the potential economic impact
of current therapeutic options.
Incidence and prevalence
Alzheimer’s disease constitutes approximately 70% of all dementia cases (Small et
al 1997; Fratiglioni et al 1999). Incidence of AD increases with age, doubling every
five to ten years. For persons between ages 65–69, 70–74, 75–79, 80–84, and 85 andClinical Interventions in Aging 2006:1(2) 144
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older, the incidence of AD has been estimated at 0.6%, 1.0%,
2.0%, 3.3%, and 8.4% (Hebert et al 1995). Prevalence also
increases exponentially with age, rising from 3% among
those 65–74, to almost 50% among those 85 or older (Evans
1990; Small et al 1998). Alzheimer’s disease affects 25
million people worldwide (Winblad 2002). In the US,
prevalence was estimated at 4.5 million in 2000, and as many
as 13.2 million (an increase of almost 3-fold) are projected
to have AD in 2050 (Hebert et al 2003). Aside from age,
other risk factors include family history of dementia, head
trauma, genetic factors (eg, apolipoprotein E [APOE] ε4
allele), being female, low education level, vascular disease,
and environmental factors (Carr et al 1997; Farrer et al 1997;
Small et al 1997; Gao et al 1998).
Because the onset of AD is insidious, many patients with
AD are not diagnosed when symptoms are mild. The
Canadian Study of Health and Aging showed that among
patients living in the community, 11% have mild AD, while
89% have moderate to severe AD (CSHAWG 1994).
Evidence suggests that moderate and severe dementia are
also under-recognized in clinical settings (Callahan et al
1995). Therefore, the already staggering figure of US$80–
100 billion in the US in caring for patients with AD is likely
an underestimate of the true disease cost (CDC and
NCCDPHP 2000). Population aging and other demographic
changes, including possible shortages of informal caregivers
because of the higher labor force participation of women
who traditionally take up the caregiving roles, may further
increase the costs of this devastating disease.
Diagnosis and assessment of
disease severity
In the clinical setting, assessment of dementia is most
commonly initiated by an informant, such as a family
member or friend. This referral is often based on observed
loss of function. For example, memory loss is commonly
reported as a loss of ability in a social or occupational area
(eg, bill paying, shopping, and household tasks) in which
there was competence, or in a behavioral change that disrupts
a social interaction (eg, asking the same question repeatedly).
Other common referrals for assessments come from medical
professionals when a patient misses an appointment or has
difficulty with adherence to a treatment regimen. The
evaluation of dementia begins with a good clinical history
and requires a knowledgeable informant to provide
information about premorbid functioning and the breadth
of deficits.
The diagnosis of AD by both Diagnostic and Statistical
Manual of Mental Disorders (DSM) and the more formal
research criteria of the National Institute of Neurological
and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association
(NINCDS–ADRDA) require memory loss in addition to
other cognitive deficits with evidence of disturbance of social
and occupational impairment (McKhann et al 1984; APA
1994). The clinical history includes questions to assess the
onset of these deficits and other social or psychological
factors that might account for these changes. Cognitive status
is often assessed with the Mini-Mental State Examination
(MMSE), which briefly assesses delayed recall, orientation,
language, and attention. In some cases, more extensive
neuropsychological assessment may be useful such as in
the presence of extremes of education (either very high or
very low) or comorbidities that may cloud the cognitive
profile.
Though not part of the diagnostic criteria, there is
growing awareness of behavioral and psychiatric symptoms
that are very common in AD and are of major importance in
managing the disease. It is commonly recognized that early
stages of the disease include apathy, withdrawal, and
depressive symptoms with later stages associated with
psychotic features (hallucinations and delusions), agitation,
and wandering.
Mild cognitive impairment (MCI) has recently been
acknowledged as a condition of cognitive impairment that
appears to be a prodrome to dementia. The amnesic form of
MCI is characterized by severe memory loss with minimal
deficits in other cognitive areas and relatively intact social
and occupational functioning. This stage may also have
associated behavioral disturbances including irritability,
apathy, and withdrawal.
Attempts have been made to stage the disease using
several instruments including the MMSE, the Geriatric
Dementia Scale (GDS), and the Clinical Dementia Rating
(CDR). Each focuses on different dimensions of disease
severity with little attention to behavioral disturbances. Table
1 offers a model of staging that includes cognition, function,
and behavior. The value in staging the disease is 2-fold: it
identifies likely present need and predicts future need. This
is particularly important in projecting future healthcare costs
associated with the disease.
Treatment
Currently there is no cure for AD. The only medications
approved by the US Food and Drug Administration (FDA)Clinical Interventions in Aging 2006:1(2) 145
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for treating mild to moderate AD (as suggested by MMSE
score between 10–26) are the cholinesterase inhibitors
(ChEI): tacrine, donepezil, rivastigmine, and galantamine.
Cholinesterase inhibitors are considered first line drugs for
treatment of AD. They inhibit acetyl cholinesterase, an
enzyme responsible for the destruction of acetylcholine,
which is reduced in AD (Becker 1991). Tacrine was the first
ChEI approved for the treatment of AD. However, because
of the risk of hepatoxicity, it is overtaken by newer
medications and is now rarely used. Donepezil, the first of
the second generation ChEIs, was approved for treatment
of AD in the US in November 1996 and became
commercially available in February 1997. Since 2001,
utilization of ChEIs increased sharply, especially for
donepezil. In 2003, 77% of ChEIs prescribed were for
donepezil. Donepezil, rivastigmine, and galantamine differ
to some extent by their pharmacological properties. Side
effects are typically related to the gastrointestinal tract,
usually mild in nature, and subside with continued use.
Patients not responding to one medication may respond to
another.
Donepezil has been shown in several randomized
controlled trials (RCT) to benefit patients’ cognitive status
(measured by the Alzheimer’s Disease Assessment Scale –
cognitive subscale, [ADAS–cog], and MMSE) compared
with placebo (Bucks et al 1996; Small et al 1998; Winblad
et al 2001; Gauthier et al 2002; Birks and Harvey 2003;
Feldman et al 2003; Courtney et al 2004). The first long-
term RCT of donepezil, the AD2000 study, found statistically
insignificant benefits in the treatment group in patient
function (measured by ADLs) (Courtney et al 2004). The
only RCT of a ChEI in the treatment of community-residing
patients with moderate to severe AD (MMSE scores between
5–17) reported significant though modest benefits of
donepezil over placebo on global function, cognition, ADLs,
and behavior (Feldman et al 2001).
Modest improvements of cognitive function, behavior,
and delays in transition to more severe stages of the disease
have been reported in patients treated with rivastigmine
(Corey-Bloom et al 1998; Rosler et al 1999; Farlow et al
2000, 2001). Two large, multi-center, double blind placebo-
control studies in Europe and the US of patients with mild
to moderately severe AD (MMSE scores 10–26) reported
improvement in ADAS-cog in the high dose group (6–12mg/
day) than the placebo and low-dose groups (1–4 mg/day)
by 4.9 and 2.6 points after 26 weeks (Corey-Bloom et al
1998; Rosler et al 1999). Since on average ADAS-cog
increases by 8 points per year, a 4.9-point improvement
suggests that treatment of rivastigmine maintains the patient
in less severe stages of AD by approximately 6 months
longer. The US study also reported significantly better
preservation in MMSE (0.85 points) and GDS (0.19 points)
Table 1 Cognitive, functional and behavioral deficits by disease stage in Alzheimer’s disease
Domain MCI Mild AD Moderate AD Severe AD
Duration 3–5 yrs 1–2 yrs 2–12 yrs 1 yr
Cognitive Memory impairment Recall/Learning Moderate memory loss Severe memory loss
(isolated deficit) Word finding difficulty Anomia Agnosia
Judgment and problem solving Visuospatial deficits Apraxia
Calculation impairment Disorientation
Confusion
Functional Occasional loss of complex Difficulty in: Loss of IADL Loss of basic ADL:
social or occupational skills Routine chores Getting lost Dressing
Complex meal preparation Difficulty dressing Grooming/bathing
Financial matters Poor eating habits Eating
Hobbies Poor hygiene habits Continence
Mobility
Behavioral Apathy, Apathy Agitation Agitation:
Irritability Delusions Delusions Verbal
Withdrawal (mild) Depression Depression Physical
Withdrawal (moderate) Insomnia Insomnia
Wandering
Abbreviations: AD, Alzheimer’s disease; IADL, instrumental activities of daily living; MCI, mild cognitive impairment.Clinical Interventions in Aging 2006:1(2) 146
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in patients in the high-dose group (DeJong et al 1989). More
recently, open label trials extending the earlier studies by
an additional 26 weeks showed that benefits of rivastigmine
continued for at least a year as measured by treatment–
placebo differences in ADAS-cog scores (Farlow et al 2000,
2001).
Preservation of cognition and function among patients
with mild to moderate AD have been reported in several
RCTs of patients treated with galantamine (24mg/day or
higher) (Raskind et al 2000; Tariot et al 2000; Wilcock et al
2000). Galantamine treatment also was shown to benefit
patients’ psychiatric and behavior symptoms and reduce
caregiver stress (Tariot et al 2000; Kaufer and Sadik 2002;
Cummings et al 2004). In these clinical trials, cognitive
function was consistently better for the treatment group
compared with the placebo group, with between group
differences ranging from 2.9–3.9 points in 6 months
(Raskind et al 2000; Tariot et al 2000; Wilcock et al 2000).
Patients’ function (measured by Alzheimer’s Disease
Cooperative Study [ADCS]–ADLs) was 2.3 points better
in the galantamine group at 5 months (Tariot et al 2000).
Studies also reported no change in Neuropsychiatric
Inventory (NPI) scores in the higher dose groups (16mg or
24mg per day) while NPI scores deteriorated among patients
in the placebo group or low dose (8mg per day) groups
(Tariot et al 2000). Recent studies separately showed
sustained benefits at 52 weeks (Raskind et al 2000; Wilcock
et al 2003). Subgroup analysis also showed that beneficial
effects of galantamine were maintained among patients 80
years or older (Tariot et al 2000; Marcusson et al 2003).
The only medication currently approved by the FDA for
the treatment of moderate to severe AD is memantine, a
noncompetitive N-methyl-D-aspartate (NMDA) receptor
inhibitor, which blocks excess release of glutamate thought
to be associated with cholinergic damage. In clinical trials,
memantine is well tolerated. Side effects include
hallucination, dizziness, confusion, headache, and tiredness.
Several RCTs in patients with moderate to severe AD showed
global and functional improvement associated with
memantine treatment (Winblad and Poritis 1999; Reisberg
et al 2003; Tariot et al 2004). A separate analysis showed
that controlling for baseline autonomy and disease severity,
the memantine group was three times more likely than the
placebo group to remain autonomous (versus dependent) at
28 weeks (Rive et al 2004).
Data on the relationship between antioxidant vitamin
intake and risk of AD have been conflicting (Engelhart et al
2002; Luchsinger et al 2003). To date there has been only
one large ADCS clinical trial of patients with moderate AD
providing evidence of efficacy of vitamin E in slowing
functional decline (Sano et al 1997). The study is a four-
arm parallel group design in which patients were
randomized into one of three active treatment groups or
placebo for 2 years. The active treatment groups consisted
of vitamin E (2000IU/day), selegiline (10mg/day), or
combination therapy. Primary outcomes are progression
from moderate to severe dementia, loss of two or three
ADLs, nursing home placement, or death. Results showed
that vitamin E and selegiline both delayed progression to
study endpoints. The average delay was 230 days for
vitamin E compared with placebo. There was no additional
benefit of combination therapy. Because of its low cost
and relative safety, vitamin E was recommended in addition
to ChEIs to slow the progression of AD. A number of other
treatments such as ginkgo biloba, antiinflammatory drugs,
and hormone replacement therapy have been suggested as
possible treatment (Parnetti et al 1997; Richards and
Hendrie 1999; Doody et al 2001). There is currently
insufficient evidence to recommend for or against their
use.
Economic impact
The costs of caring for patients with AD have been
extensively studied (Ernst and Hay 1994; Stommel et al
1994; Max et al 1995; Hux et al 1998; Leon and Neumann
1998; Gutterman et al 1999; Langa et al 2001; Moore et al
2001; Murman et al 2002, 2003; Small et al 2002; Andersen
et al 2003). In terms of total costs to society, AD is the third
most costly disease in the US after cancer and coronary heart
disease (Meek et al 1998). Average annual costs of caring
for patients with AD have been estimated at US$80–100
billion in the US (CDC and NCCDPHP 2000). Total costs
include direct, indirect, and intangible costs. Direct costs
include multiple dimensions of medical care costs (eg,
nursing home care, medications, physician visits,
hospitalizations) and nonmedical care costs (eg, home health
aides, respite care, adult daycare). Indirect costs are imputed
values of resources lost due to the illness, including
premature deaths, patient and caregiver lost productivity,
and unpaid caregiving time. Intangible costs are those related
to pain and suffering endured by patients and families, and
those related to deterioration of patient and caregiver quality
of life (QoL). Because the inclusion of intangible costs in
economic studies is highly controversial and their evaluation
notoriously difficult, most studies have focused on
estimating direct and indirect costs of AD.Clinical Interventions in Aging 2006:1(2) 147
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Several important factors that influence the cost of AD
have been identified in the literature, including dementia
disease severity (Rice et al 1993; Max et al 1995; Ernst et al
1997; Hux et al 1998; Leon and Neumann 1998; Souetre et
al 1999; Taylor and Sloan 2000; Moore et al 2001; Small et
al 2002; Zhu et al 2003), comorbid medical conditions (Leon
and Neumann 1998; Gutterman et al 1999; Fillit 2000),
behavioral problems (Beeri et al 2002; Murman et al 2002;
Zhu et al 2003), and extrapyramidal signs (Murman et al
2003). The presence of comorbid conditions significantly
increases the cost of caring for patients with AD. The effects
of comorbidities are particularly important in AD patients
as the majority of them have at least one comorbid condition.
One study reported that 93% of AD patients had at least one
comorbid condition, and 61% had three or more (Fillit 1999).
A study of Medicare enrollees reported that each comorbid
condition in patients with AD was associated with
disproportionately higher cost (US$10435) than in patients
without AD (US$526) (Fillit 2000). Other studies reported
that the cost of managing comorbid conditions also was
greater among AD patients (Gutterman et al 1999). It has
been hypothesized that cognitive decline with AD may be
associated with under-reporting of all symptoms and
complicate the management of other chronic conditions
(Rice et al 1993; Fillit 1999).
Alzheimer’s disease costs depend strongly on caregiving
settings. Early in the disease, indirect costs often exceed
direct costs as the majority of AD patients are cared for by
informal caregivers in the community. For patients living in
the community, some 60%–70% of the total cost of caring
for AD patients has been attributed to informal caregiving.
When patients are institutionalized, costs shift from indirect
to direct (Huang et al 1988; Ernst and Hay 1994; Wimo et
al 1997; Leon and Neumann 1998). About three-fourths of
the total costs of AD occur during severe stages of AD,
mainly due to institutionalization (Wimo, Winblad, Stoffler,
et al 2003). One study suggests that relatively small delays
in the onset and progression of dementia could substantially
reduce disease costs (Brookmeyer et al 1998). It has been
estimated that a 1-month delay in institutionalization of a
patient with moderate to severe AD would result in savings
of US$1863 per month (Leon and Neumann 1998). The
incidence and prevalence of AD is likely to rise as the
population continues to age, and the already staggering costs
of caring for patients with AD also will increase.
An important objective of economic analysis is to show
the value of a medical treatment or intervention. This is a
complex issue. For example, if a treatment delays
institutionalization, but does not affect survival, the overall
disease costs may be lowered if reductions in the cost of
institutionalization outweigh the increases in treatment cost.
Cost reductions, however, may be partially offset by potential
increases in informal caregiving costs. If on the other hand,
treatment prolongs survival, lifetime disease cost may in
fact increase. Further complicating the issues are the possible
impact on patient and family QoL. However, these important
issues are often neglected.
Several different methods have been used in analyzing
the effects of treatment on the costs of caring for patients
with AD, including RCT, matched-control trials, pre-post
designs, observational studies, and modeling analyses. Each
of these methods is subject to a number of criticisms.
Collecting resource utilization data prospectively in large,
multicentered RCTs is a preferred method in economic
analyses. However, while these analyses have superior
internal validity, they are expensive to conduct and are often
limited by their relatively short time horizon, and may not
be applicable outside the trial settings. Because other studies
are not of random design, possible selection effects cannot
be ruled out. For example, in matched-control trials,
caregivers of patients who tolerated the drugs better may
have selectively delayed institutionalization and artificially
lowered the costs of care. Because utilization and costs are
expected to increase overtime as a result of disease
progression, possible cost savings in studies with pre-post
designs may be underestimated. In pre-post studies, it also
is not meaningful to adjust for other covariates that influence
disease cost (eg, comorbid conditions).
Dementia patients are expected to live approximately
seven to ten years after diagnosis (Brookmeyer et al 2002;
Cummings and Cole 2002). Pharmacological treatments may
have substantial effects on long-term costs, which is
particularly important because of the progressive nature of
the disease. However, long-term effects of pharmacological
treatments are not yet known. In the absence of long-term
clinical data, modeling studies often use clinical data from
short periods of time (eg, 6 months, 26 months) and project
longer term costs (2, 5, or 10 years) relying on data from a
variety of external sources. The underlying assumption is
that clinical benefits observed in the short run will persist at
the same rate at later time points. This assumption may not
be valid. Making matters worse, clinical data often are
derived from other countries. It is possible that there may
be differences in drug efficacy between populations in
different countries that are yet unknown. Therefore, even if
studies are robust to plausible changes in key variables,Clinical Interventions in Aging 2006:1(2) 148
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Table 2 Pharmacoeconomic studies with approved treatments for Alzheimer’s disease
Study type Author Drug Study length Costs included AD severity Per patient cost Country
studied savings
RCT Courtney et al 2004 Donepezil 5 yrs Direct medical cost Mild to moderate No cost difference UK
and cost of caregiver
time
RCT Feldman et al 2004 Donepezil 24 wks Patient and caregiver Moderate to Direct medical cost: Canada
direct medical cost, severe US$21; informal care
and cost of caregiver cost: US$265
time
RCT Sano et al 2003 Galantamine 6 months Cost of caregiver Mild to moderate 32 minutes per day US
time
RCT Wimo, Winblad, Memantine 28 wks Direct medical cost Moderate to Direct medical cost: US
Stoffler, et al 2003 and cost of caregiver severe US$1090 per month;
time caregiving time:
51.5 hrs per month
Matched- Small et al 1998 Donepezil 6 months Direct medical costs Not specified No cost difference US
controlled
Matched- Hill et al 2002 Donepezil 12 months Direct medical costs Not specified US$3891 US
controlled
Pre-post Fillit et al 1999 Donepezil Pre-treatment: Direct medical costs Not specified US$2.11 higher US
design 15 months per day
Post-treatment:
7 months
Modeling Stewart et al Donepezil Markov, 5 yrs Direct medical costs Mild to moderate No cost difference UK
study 1998
Modeling Neumann et al Donepezil Markov, 2 yrs Direct medical cost Mild US$73 US
study 1999 and cost of caregiver
time
Modeling O’Brien et al 1999 Donepezil Markov, 5 yrs Direct medical cost Mild to moderate CA$882 Canada
study and cost of caregiver
time
Modeling Hauber, Rivastigmine Hazard, 2 yrs Direct medical cost Mild to moderate, US$2.51 per day at Canada
study Gnanasakthy, and cost of caregiver moderate 1 yr; US$4.93
Mauskopf, et al 2000 time per day at 2 yr
Modeling Hauber, Rivastigmine Cox Direct medical cost Mild to moderate Mild AD: US$4289; US
study Gnanasakthy, proportional of caregiver time moderate AD:
Snyder, et al 2000 hazard model, US$2290
2 yrs
Modeling Getsios et al 2001 Galantamine AHEAD, Direct medical costs Mild to moderate, Mild to moderate: Canada
study 10 yrs moderate CA$528; moderate
disease: US$2533
Modeling Caro et al 2002 Galantamine AHEAD, Direct medical costs Mild to moderate, US$1676 Netherlands
study 10 yrs moderate
Modeling Garfield et al 2002 Galantamine AHEAD, Direct medical costs Mild to moderate, Mild to moderate: Sweden
study 10 yrs moderate ¤3131; moderate:
¤5594
Modeling Ward et al 2003 Galantamine AHEAD, Direct medical costs Mild to moderate £1380 UK
study 10 yrs
Modeling Migliaccio-Walle Galantamine AHEAD, Direct medical costs Mild to moderate US$2408–US$3601 US
study et al 2003 10 yrs
Modeling Jones et al 2004 Memantine Markov, 2 yrs Direct medical costs Moderately severe £1,963 UK
study to severe
Modeling Francois et al 2004 Memantine Markov, 5 yrs Direct medical costs Moderately severe ¤1,687 Finland
study to severe
Abbreviations: AD, Alzheimer’s disease; RCT, randomized controlled trials.Clinical Interventions in Aging 2006:1(2) 149
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results may not be applicable to other settings or regions. In
the very long-term studies, proper discounting of costs has
not been employed. Table 2 highlights the findings of
pharmacoeconomic studies.
Randomized controlled trials
The first long-term RCT of donepezil, the AD2000 study,
did not find any difference in disease costs and caregiving
time between treatment and placebo groups (Courtney et al
2004). In the Moderate to Severe Alzheimer’s Disease
(MSAD) study of patients with moderate to severe AD,
excluding the costs of prescription drugs, donepezil
treatment was associated with a decrease of US$224 in total
direct medical cost at 24 months (Gauthier et al 2002). Most
of the cost reduction, however, was offset by the higher cost
of prescription drugs: When prescription drug costs were
included, total direct medical costs were only US$23 less
for the donepezil group. Donepezil treatment also was
associated with almost an hour per day less of caregiving
time. Using the minimum hourly wage (US$4.63) as a
conservative measure of caregiver’s time, the authors found
donepezil treatment reduced total informal costs by US$265
per patient per year (Feldman et al 2003, 2004).
Several studies have reported the effects of galantamine
on informal caregiver time. Results from a 6-months RCT
showed that while time spent supervising patients in the
placebo group increased by 2 hours a day at 6 months, there
was no change in the time spent in the galantamine group
(Blesa 2000). In addition, there was a net gain of an hour a
day in the time spent on helping with ADLs in the
galantamine group (a 23 minute per day increase in the
placebo group vs 38 minute decrease in the galantamine
group). Combining data from two similarly designed clinical
trials of patients with mild to moderate AD, Sano and
colleagues (2003) examined the effects of galantamine on
time spent helping with ADLs and time patients could be
left unsupervised (measured by the Allocation of Caregiving
Time Survey). Results showed that compared with caregivers
of patients in the placebo group, caregivers in the
galantamine group were more likely to report decreases
(41% vs 37%), maintenance (19% vs 15%), or smaller
increases (26% vs 35%) in time helping patients. On average,
caregivers in the galantamine group provided 3.5 hours of
less care per week (32 minutes per day) than the control
group. Among patients with moderate AD, treatment effects
were greater.
A recent RCT of the effects of 28 weeks of memantine
treatment found that controlling for baseline characteristics
(patient and caregiver sex, caregiving time, caregiver–patient
relationship), patients receiving memantine were less likely
to be institutionalized and needed an average of 51.5 hours
per month less caregiving time than those receiving placebo
(Wimo, Winblad, Stoffler, et al 2003). Mainly because of
the cost of memantine, direct medical costs were US$160
per month higher in the memantine group. However,
increases in direct medical costs were offset by savings in
caregiving costs (US$824 per month) and direct nonmedical
costs (US$431 per month). Total costs to society were
US$1090 lower in the memantine group per month.
Matched-controlled trials
One of the first economic analyses of donepezil in the
treatment of AD followed 108 community-living AD patients
in the US taking donepezil for 6 months or longer and 268
patients matched on age, sex, and comorbidity and estimated
total direct medical costs (doctor visits, emergency use,
hospital stays, and prescription drugs) for the two groups
(Small et al 1998). The study found rate of
institutionalization was significantly lower for the donepezil
group than the control group (5% vs 10%), and cost of
institutional care was accordingly lower (US$710 vs $1487).
The lower institutional cost largely offsets the higher cost
of prescription drugs (US$1072 vs $392). As a result, there
were no group differences in total direct medical costs
(US$3443 for the donepezil group vs US$3476 for the
placebo group).
A recent study using claims data in a large managed care
organization (MCO) compared costs for 204 AD patients
receiving donepezil with a control group of 204 AD patients
who had matching characteristics, but who were not
receiving donepezil. After controlling for age, gender,
pharmacy benefits, comorbid conditions, and complications
of dementia, the annual costs for medical services and
prescription drugs were found to be US$3891 lower for the
donepezil group (Hill et al 2002). Cost savings were mostly
due to lower use of hospitalization and skilled nursing
facilities.
Pre-post design
Fillit and colleagues examined cost of medical services and
prescription drugs from claims data from a sample of AD
patients (n=70) in an MCO before and after donepezil use
(Fillit et al 1999). Average lengths of follow-up in the pre-
and post- donepezil period were approximately 15 and 7
months. Results showed that while median per diem cost
for medical services decreased by US$1.22 after donepezilClinical Interventions in Aging 2006:1(2) 150
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use, because of the increase in prescription drug cost by
US$2.59 per day (US$946 per year), total per diem cost
rose by US$2.11 per day (US$771 per year).
Modeling studies
A number of studies have modeled longer-term effects of
donepezil on disease costs. Results depend on the
assumptions made by the models, including the duration of
the drug effect and whether treatment delayed
institutionalization. Steward and colleagues (1998) modeled
the costs of donepezil for 5 years and found the drug to be
approximately cost neutral. Neumann and colleagues
simulated the effects of donepezil using data from a 24 week
RCT and a national longitudinal data of dementia patient
(Morris et al 1989; Rogers et al 1990; Neumann et al 1999).
They found that the costs of donepezil were offset by a delay
to more severe disease stages if drug effects exceeded 2
years. O’Brien and colleagues, on the other hand, using data
from the same clinical trial, estimated a cost savings of
CA$882 associated with donepezil treatment (Rogers et al
1990; O’Brien et al 1999).
Several economic studies estimated potential cost savings
attributable to the use of rivastigmine. Two similar studies
in the US and Canada found that rivastigmine delayed the
transition to more severe stages of AD and
institutionalization and resulted in modest savings in direct
costs of caring for patients with AD (Hauber, Ganasakthy,
Mauskopf, et al 2000; Hauber, Gnanasakthy, Snyder, et al
2000). In the Canadian study, rivastigmine treatment was
associated with an overall delay in transition to the next
disease stage by 5 days in 6 months, 36 days in one year,
and 137 days in two years, with cost savings of CA$0.71,
CA$2.51, and CA$4.93 per day per patient (Hauber,
Gnanasakthy, Snyder, et al 2000). Delays in disease
progression and resulting cost savings are greater for patients
who begin treatment while in the milder stages of the disease.
Cost savings for patients who began treatment during mild
stages of AD were mostly from delays in transitions to
moderate AD. For those who began treatment during
moderate stages of AD, cost savings were mostly attributable
to delayed institutionalization during the first year of
treatment. In the US study, rivastigmine treatment was
associated with delayed disease progression for patients who
started treatment in the mild stage by 56 days in 2 years,
then delays from moderate to severe stage by 69 days
(Hauber, Gnanasakthy, Snyder, et al 2000). For patients who
began treatment at moderate stages of the disease,
rivastigmine treatment was associated with delayed disease
progression to severe stage by 51 days in 2 years. Cost
savings were estimated to be US$132 and US$137 for mild
and moderate AD at 6 months, respectively. After two years
of treatment, cost savings were estimated to be US$4389
and US$2290 for mild and moderate AD, respectively. As
in the Canadian study, most cost savings were attributed to
delays in institutionalization. Neither study included cost
of treatment itself, which may reduce the potential cost
saving. However, this problem may not be severe as the costs
of the drug therapy per se are moderate.
To date, most pharmacoeconomic analyses of
galantamine have been based on Assessment of Health
Economics in Alzheimer’s Disease (AHEAD), a model
developed to estimate long-term health and economic effects
of galantamine treatment for patients with mild to moderate
AD from short-term clinical data (Caro et al 2001). The
AHEAD model has two parts: the first part is a 6-month
short-term model based directly on trial data; the second
part is a long-term (10-year) model that predicts time to
death or need for full time care (FTC), defined to be
consistent requirement for care and supervision for the great
part of the day, regardless of care setting. Patients who do
not need FTC are assumed to live at home. The prediction
equations used in AHEAD are derived from published
equations of estimating the risk of needing FTC or death
(Stern et al 1997).
Because the AHEAD model predicts equivalent FTC not
specific to location of care, it can be adapted to diverse
healthcare systems by customizing country specific costs
and other inputs (eg, care types and resource use). Possibly
because the same underlying model structure was used,
similar results have been reported in studies from different
countries (Getsios et al 2001; Caro et al 2002; Garfield et al
2002; Ward et al 2003). Most studies reported net savings
with galantamine treatment over 10 years. Per patient net
cost savings ranged from ¤313, CA$788, £3376, US$2408,
and NLG3050 for patients with initially mild to moderate
AD. Several studies that estimated potential savings among
patients initially with moderate AD reported substantially
higher cost saving over time, ranging from US$2533 to
US$4995 (Getsios et al 2001; Garfield et al 2002). Not
surprisingly, countries with lower institutional care costs
were associated with the lower potential cost savings.
Two similar studies to date estimated potential economic
gains of memantine treatment over longer treatment period
(Francois et al 2004; Jones et al 2004). Both studies
constructed a Markov model to simulate patient progression
through a series of health states related to severity,Clinical Interventions in Aging 2006:1(2) 151
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dependency, and residential status (community vs
institutionalization). Patient dependency was measured by
ADCS–ADL modified for severe dementia (Galasko et al
2000). For both studies, data on dependency,
institutionalization, and transition probabilities from one
health state to another were derived from earlier studies
(Reisberg et al 2003). Epidemiological and resource
utilization data were country specific. The UK study
included only utilization of formal services over 2 years
(Jones et al 2004). The Finnish study additionally included
utilization of informal care over 5 years (Francois et al 2004).
Both studies found a 40% increase in time in independence
(1.3 and 4.1 additional months in the UK and Finnish study,
respectively) and a 15% increase in time before
institutionalization (0.8 and 1 additional month in the UK
and Finnish study, respectively) in the memantine group
compared with the placebo group. Cost savings were
estimated to be £1963 over 2 years and ¤1687 over 5 years.
These studies suggest that memantine provides cost savings
compared with no pharmacological treatment. The studies
also may have underestimated the overall benefit of
memantine because the assumed duration of clinical efficacy
was shorter than the duration of memantine therapy.
In summary, while few studies have used a prospective
health economics design to assess of resource utilization,
most studies suggest beneficial effects of treatment with
potential cost savings. Various degrees of cost savings have
been reported depending on the type of economic model,
treatment evaluated, and region used in the studies. Because
different methods have been used in these evaluations, direct
comparisons of the results are difficult.
Unpaid home care
An integral part of the management of AD is the caregivers
of the afflicted patients. Most AD patients live in the
community, many with the caregiver, and the bulk of the
costs of caring for these patients often are borne by these
unpaid (informal) family caregivers. On average, informal
caregivers provide 70 hours of care per week to AD patients
(Rice et al 1993; Stommel et al 1994; Max et al 1995). Larger
components of the total cost of caring for patients living in
the community are unpaid caregiving time and caregivers’
lost earnings (Moore et al 2001). In addition, more than 60%
of formal services provided for AD patients are financed by
the family, regardless of care setting (Rice et al 1993).
Caregiving families’ out of pocket expenditures for non-
reimbursable medical equipment and services, prescription
drugs, paid care of non-family persons have been estimated
at US$4564 annually (Stommel et al 1994).
Caregiver burden associated with AD is not only
financial. Caregivers of AD patients are twice as likely to
provide the most intense level of care than other caregivers
(AA and NAC 1999). Numerous studies have shown higher
rates of depression and greater physical and psychiatric
problems among AD caregivers (Teri and Truax 1994;
Dunkin and Anderson-Hanley 1998; Burns 2000). They also
are more likely than non-caregivers to need physician visits
and prescription medications (Baumgarten et al 1997;
Dunkin and Anderson-Hanley 1998; Burns 2000). In many
cases, the physical or psychological problems experienced
by the caregivers are due to the stress of prolonged
caregiving. Not surprisingly, caregiver burden rises with
disease severity. As patients deteriorate, the emotional and
physical toll of caregiving can increase health risks for the
caregivers. Many caregivers become ‘hidden patients’
themselves.
Issues related to caregiver burden and caregiver time
commitments often are further complicated as informal
caregivers are most commonly spouses of the AD patients
and their adult children. The spouses of AD patients often
are themselves elderly and suffer from compromised health
and functioning (Stone et al 1987). Second to spouses, adult
children often provide care to elderly parents who are
afflicted with AD. Many of these adult children are employed
and have children of their own (Beach 1997). Since women
have traditionally been taken up the majority of caregiving
roles, the steady increase in women’s labor force
participation in recent decades have raised questions on the
future availability of informal caregivers. Currently, 61.9%
of women age 16 and older in the US are in the labor force
(Szafran 2002). Among middle-aged women, who are more
likely than younger women to become caregivers, labor force
participation rates are even higher. Many studies documented
the conflicts between women’s labor force participation and
informal caregiving, and showed that caregivers who were
employed were more likely to withdraw from the labor
market, be late or absent more often, take unpaid leave, or
reduce their hours of work because of their caregiving
responsibilities (Ettner 1995). Owing to absenteeism and
lost productivity because of caregiving responsibilities,
caregivers in the workforce cost US businesses US$36
billion annually in indirect costs (Koppel 2002).
The preference of patients and families for home care
for as long as possible suggests that promoting non-
institutional care for these patients should become a priority.Clinical Interventions in Aging 2006:1(2) 152
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Psychosocial interventions, such as caregiver training,
counseling, and support groups, may help reduce caregiver
burden and help maintain patients in the community
(Mittelman et al 1996; Hepburn et al 2003). Paid home care,
including social services, home health aides, respite and adult
day care also may provide relief for the caregivers, although
their effects on reducing caregiver burden have not been
established. Several studies have raised concerns of the
possible paradoxical effects on caregivers of antidementia
drugs: Delayed institutionalization may prolong informal
caregiving and increase the burden of family members and
caregivers (Max 1996; Wimo et al 1999). However, studies
have consistently reported beneficial effects of
pharmacological treatment including fewer caregiving hours
(Feldman et al 2003; Wimo, Winblad, Engedal, et al 2003),
and lower levels of stress and difficulty of caregiving (Fillit
et al 2000; Kaufer and Sadik 2002). These studies suggest
that previous reports of modest cost savings of
pharmacological treatment may be underestimated.
Continued home care for patients under pharmacological
treatment may reduce caregiver burden and healthcare costs,
and ultimately improve patient and caregiver QoL.
Discussion
Alzheimer’s disease is a devastating chronic disease that
significantly increases health care costs and affects the lives
of the afflicted patients and their caregivers. The growing
elderly population and the possible shortage of informal
caregivers raise patients’ healthcare needs and costs even
higher. The physical and psychological toll of caregiving
can increase health risks for the caregivers and increase their
own medical care costs. Because caregivers are an integral
part of the caring for patients with AD, management of AD
needs to treat patients and caregivers as a whole. Recent
developments in pharmacological therapies such as ChEIs
have been shown to improve patients’ cognition and function
and reduce symptoms in addition to reducing informal
caregiving time and caregiver burden. To better understand
the cost implications of long-term treatment effects,
economic analyses that use prospective, long-term data
collected along with clinical data are needed. Improved
pharmacological treatment and management of AD may help
control healthcare costs and improve the QoL of patients
and families.
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